Published in Proc Natl Acad Sci U S A on January 07, 2004
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol (2004) 7.68
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest (2005) 5.90
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer (2009) 5.31
Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev (2008) 4.52
Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol (2011) 4.50
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
Revisiting global gene expression analysis. Cell (2012) 3.63
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
Application of genome-wide expression analysis to human health and disease. Proc Natl Acad Sci U S A (2005) 3.49
Inferring pathway activity toward precise disease classification. PLoS Comput Biol (2008) 3.48
Key issues in conducting a meta-analysis of gene expression microarray datasets. PLoS Med (2008) 3.31
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. Neoplasia (2006) 3.08
Cell- and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev (2007) 2.96
Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity. Nat Cell Biol (2013) 2.90
A DNA microarray survey of gene expression in normal human tissues. Genome Biol (2005) 2.90
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell (2008) 2.87
Genomic profiling identifies TITF1 as a lineage-specific oncogene amplified in lung cancer. Oncogene (2008) 2.83
JARID1B is a histone H3 lysine 4 demethylase up-regulated in prostate cancer. Proc Natl Acad Sci U S A (2007) 2.45
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res (2012) 2.41
Molecular sampling of prostate cancer: a dilemma for predicting disease progression. BMC Med Genomics (2010) 2.40
Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol (2010) 2.38
Effects of threshold choice on biological conclusions reached during analysis of gene expression by DNA microarrays. Proc Natl Acad Sci U S A (2005) 2.37
Array-based comparative genomic hybridization identifies localized DNA amplifications and homozygous deletions in pancreatic cancer. Neoplasia (2005) 2.35
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
The mutational landscape of prostate cancer. Eur Urol (2013) 2.14
Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal (2009) 2.11
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet (2013) 2.11
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Anni 2.0: a multipurpose text-mining tool for the life sciences. Genome Biol (2008) 2.04
The rationale for targeting the LOX family in cancer. Nat Rev Cancer (2012) 2.02
Clustering cancer gene expression data: a comparative study. BMC Bioinformatics (2008) 2.00
Biclustering of gene expression data by Non-smooth Non-negative Matrix Factorization. BMC Bioinformatics (2006) 1.98
Feature selection and molecular classification of cancer using genetic programming. Neoplasia (2007) 1.94
3'-end sequencing for expression quantification (3SEQ) from archival tumor samples. PLoS One (2010) 1.91
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state. Cell Cycle (2008) 1.90
RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1. Lancet Oncol (2014) 1.88
Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene (2008) 1.88
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Mining CK2 in cancer. PLoS One (2014) 1.87
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun (2014) 1.84
Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell (2012) 1.75
Stromal responses among common carcinomas correlated with clinicopathologic features. Clin Cancer Res (2013) 1.75
GeneXplorer: an interactive web application for microarray data visualization and analysis. BMC Bioinformatics (2004) 1.75
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Semi-supervised recursively partitioned mixture models for identifying cancer subtypes. Bioinformatics (2010) 1.63
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
A novel role of myosin VI in human prostate cancer. Am J Pathol (2006) 1.59
The α₂β₁ integrin is a metastasis suppressor in mouse models and human cancer. J Clin Invest (2010) 1.55
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
TMPRSS2-ERG gene fusions induce prostate tumorigenesis by modulating microRNA miR-200c. Oncogene (2013) 1.51
Multiple oncogenic pathway signatures show coordinate expression patterns in human prostate tumors. PLoS One (2008) 1.46
CRNDE: A Long Non-Coding RNA Involved in CanceR, Neurobiology, and DEvelopment. Front Genet (2012) 1.45
Sample size for detecting differentially expressed genes in microarray experiments. BMC Genomics (2004) 1.45
Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol (2014) 1.43
Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring. Genome Biol (2007) 1.43
Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies. PLoS One (2016) 1.42
Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature (2015) 1.42
GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer (2008) 1.41
The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling. Cancer Res (2010) 1.41
SPARC: a matricellular regulator of tumorigenesis. J Cell Commun Signal (2009) 1.41
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature (2017) 1.40
Genomic profiling identifies GATA6 as a candidate oncogene amplified in pancreatobiliary cancer. PLoS Genet (2008) 1.39
Gene-expression patterns reveal underlying biological processes in Kawasaki disease. Genome Biol (2007) 1.39
Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Res (2016) 1.39
Defining aggressive prostate cancer using a 12-gene model. Neoplasia (2006) 1.39
Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics (2006) 1.39
MetaQC: objective quality control and inclusion/exclusion criteria for genomic meta-analysis. Nucleic Acids Res (2011) 1.35
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling. Oncogene (2009) 1.34
Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness. Oncogene (2011) 1.33
Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate (2009) 1.33
Glycoproteomic analysis of prostate cancer tissues by SWATH mass spectrometry discovers N-acylethanolamine acid amidase and protein tyrosine kinase 7 as signatures for tumor aggressiveness. Mol Cell Proteomics (2014) 1.33
SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation. Mol Cell Biol (2011) 1.30
CARM1 methylates chromatin remodeling factor BAF155 to enhance tumor progression and metastasis. Cancer Cell (2014) 1.30
MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther (2009) 1.30
Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes. Bioinformatics (2009) 1.29
Expression profiling of primary tumors and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Pathol (2005) 1.29
COSINE: COndition-SpecIfic sub-NEtwork identification using a global optimization method. Bioinformatics (2011) 1.29
COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion. J Clin Invest (2010) 1.28
Advances in translational bioinformatics: computational approaches for the hunting of disease genes. Brief Bioinform (2009) 1.27
Detecting disease associated modules and prioritizing active genes based on high throughput data. BMC Bioinformatics (2010) 1.27
A kernel-based integration of genome-wide data for clinical decision support. Genome Med (2009) 1.26
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Zag expression during aging suppresses proliferation after kidney injury. J Am Soc Nephrol (2008) 1.25
Novel biomarkers for prostate cancer including noncoding transcripts. Am J Pathol (2009) 1.25
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Molecular portraits of human breast tumours. Nature (2000) 94.14
Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science (1999) 83.27
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 64.32
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A (2001) 24.34
A molecular signature of metastasis in primary solid tumors. Nat Genet (2002) 21.36
Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med (2002) 21.28
Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A (2001) 17.36
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell (2002) 11.83
Cancer burden in the year 2000. The global picture. Eur J Cancer (2001) 10.47
Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res (2001) 6.73
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling. Cancer Res (2001) 4.51
Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res (2002) 4.42
International trends and patterns of prostate cancer incidence and mortality. Int J Cancer (2000) 3.73
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res (2001) 3.29
Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res (2002) 2.84
A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res (2002) 2.65
Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol (1995) 2.41
A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell (1996) 2.39
Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol (2001) 2.32
MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology (1994) 2.08
Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Int J Cancer (2003) 1.69
Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol (1995) 1.63
Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the alpha vbeta 5 integrin. J Biol Chem (2001) 1.52
Neuropilin 1 and neuropilin 2 co-expression is significantly correlated with increased vascularity and poor prognosis in nonsmall cell lung carcinoma. Cancer (2002) 1.48
Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer. Clin Cancer Res (2001) 1.43
MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. J Clin Pathol (1998) 1.41
Immunohistochemical localization of Zn-alpha 2-glycoprotein in normal human tissues. J Histochem Cytochem (1991) 1.40
Basal cell hyperplasia, adenoid basal cell tumor, and adenoid cystic carcinoma of the prostate gland: an immunohistochemical study. Hum Pathol (1988) 1.37
National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology (1998) 1.32
Prostate short-chain dehydrogenase reductase 1 (PSDR1): a new member of the short-chain steroid dehydrogenase/reductase family highly expressed in normal and neoplastic prostate epithelium. Cancer Res (2001) 1.30
MUC1 Expression in Prostate Carcinoma: Correlation with Grade and Stage. Mol Urol (1999) 1.20
Coexpression of MUC1 glycoprotein with multiple angiogenic factors in non-small cell lung cancer suggests coactivation of angiogenic and migration pathways. Clin Cancer Res (2000) 1.19
Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res (2001) 1.16
Mucin core protein expression in extrahepatic bile duct carcinoma is associated with metastases to the liver and poor prognosis. Cancer (1999) 1.15
Expression of Zn-alpha 2-glycoprotein and PSP-94 in prostatic adenocarcinoma. An immunohistochemical study of 88 cases. Am J Pathol (1990) 1.14
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Sparse inverse covariance estimation with the graphical lasso. Biostatistics (2007) 24.38
GO::TermFinder--open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics (2004) 20.23
Development of the human infant intestinal microbiota. PLoS Biol (2007) 18.91
Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell (2002) 17.32
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genet (2003) 14.56
Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A (2002) 12.68
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
Saccharomyces Genome Database (SGD) provides secondary gene annotation using the Gene Ontology (GO). Nucleic Acids Res (2002) 10.65
Empirical bayes methods and false discovery rates for microarrays. Genet Epidemiol (2002) 10.56
SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res (2003) 10.28
Saccharomyces Genome Database (SGD) provides tools to identify and analyze sequences from Saccharomyces cerevisiae and related sequences from other organisms. Nucleic Acids Res (2004) 10.18
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med (2004) 9.81
A penalized matrix decomposition, with applications to sparse principal components and canonical correlation analysis. Biostatistics (2009) 9.40
Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol (2004) 9.38
Gene Ontology annotations at SGD: new data sources and annotation methods. Nucleic Acids Res (2007) 9.03
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
Precision and functional specificity in mRNA decay. Proc Natl Acad Sci U S A (2002) 8.20
Introductory science and mathematics education for 21st-Century biologists. Science (2004) 7.69
Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol (2004) 7.68
Genome-wide analysis of mRNA translation profiles in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2003) 7.45
Molecular characterisation of soft tissue tumours: a gene expression study. Lancet (2002) 7.05
Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A (2002) 6.98
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91
Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med (2007) 6.80
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A (2005) 6.54
Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci U S A (2003) 6.49
Extensive association of functionally and cytotopically related mRNAs with Puf family RNA-binding proteins in yeast. PLoS Biol (2004) 6.38
The Stanford Microarray Database: data access and quality assessment tools. Nucleic Acids Res (2003) 6.31
A Bayesian framework for combining heterogeneous data sources for gene function prediction (in Saccharomyces cerevisiae). Proc Natl Acad Sci U S A (2003) 6.19
Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med (2006) 6.04
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Saccharomyces Genome Database (SGD) provides biochemical and structural information for budding yeast proteins. Nucleic Acids Res (2003) 5.69
Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosomes Cancer (2006) 5.39
Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One (2012) 5.28
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
Characteristic genome rearrangements in experimental evolution of Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (2002) 4.97
Anatomic demarcation by positional variation in fibroblast gene expression programs. PLoS Genet (2006) 4.75
Cell type-specific gene expression differences in complex tissues. Nat Methods (2010) 4.75
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A (2003) 4.67
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
Autoantigen microarrays for multiplex characterization of autoantibody responses. Nat Med (2002) 4.54
Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol (2006) 4.49
Diverse RNA-binding proteins interact with functionally related sets of RNAs, suggesting an extensive regulatory system. PLoS Biol (2008) 4.34
Concordant regulation of translation and mRNA abundance for hundreds of targets of a human microRNA. PLoS Biol (2009) 4.32
Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol (2003) 4.28
Coordination of growth rate, cell cycle, stress response, and metabolic activity in yeast. Mol Biol Cell (2007) 4.27
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A (2012) 4.20
The Stanford Microarray Database accommodates additional microarray platforms and data formats. Nucleic Acids Res (2005) 4.17
Endothelial cell diversity revealed by global expression profiling. Proc Natl Acad Sci U S A (2003) 3.98
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci U S A (2009) 3.87
Stereotyped and specific gene expression programs in human innate immune responses to bacteria. Proc Natl Acad Sci U S A (2002) 3.85
The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol (2004) 3.84
Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. Genes Cancer (2010) 3.78
Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell (2004) 3.73
A transcriptional profile of aging in the human kidney. PLoS Biol (2004) 3.69
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Systematic analysis of breast cancer morphology uncovers stromal features associated with survival. Sci Transl Med (2011) 3.68
The Stanford Microarray Database: implementation of new analysis tools and open source release of software. Nucleic Acids Res (2006) 3.66
Regularized linear discriminant analysis and its application in microarrays. Biostatistics (2006) 3.66
Nonparametric methods for identifying differentially expressed genes in microarray data. Bioinformatics (2002) 3.65
Genome Snapshot: a new resource at the Saccharomyces Genome Database (SGD) presenting an overview of the Saccharomyces cerevisiae genome. Nucleic Acids Res (2006) 3.59
The repertoire and dynamics of evolutionary adaptations to controlled nutrient-limited environments in yeast. PLoS Genet (2008) 3.58
A framework for feature selection in clustering. J Am Stat Assoc (2010) 3.46